Literature DB >> 18026609

[Community-acquired methicillin-resistant Staphylococcus aureus in Bogotá, Colombia: Public Health implications].

Jorge Alberto Cortes1, Carlos Andrés Gómez, Sonia Isabel Cuervo, Aura Lucía Leal.   

Abstract

OBJECTIVE: Determining the prevalence of methicillin-resistant Staphylococcus aureus (CA-MRSA) and susceptibility to erythromycin and clindamycin (resistance profile suggestive of being CA-MRSA) in community isolates from de GREBO's database from 2001-2005.
MATERIALS AND METHODS: GREBO's database has been complied since 2001, using more than 22 hospitals in Bogota. S. aureus resistance profiles were determined from community isolates. Whonet 5.3 software and CLSI breakpoints (2003) were used.
RESULTS: 2,308 S. aureus community isolates were identified. 618 (26,8 %) were methicillin-resistant Staphylococcus aureus (MRSA). 74 (3,2 %) MRSA exhibited susceptibility to all other antibiotics (erythromycin, clindamycin), suggesting that S. aureus belonged to CA-MRSA.
CONCLUSIONS: CA-MRSA might have emerged in Bogotá thereby having a profound implication for public health due to possible dissemination in the community and because antibiotic protocols for emergency settings should be changed. The results of our study suggested that CA-MRSA could be more common in Bogotá than currently expected.

Entities:  

Mesh:

Year:  2007        PMID: 18026609     DOI: 10.1590/s0124-00642007000300013

Source DB:  PubMed          Journal:  Rev Salud Publica (Bogota)        ISSN: 0124-0064


  2 in total

1.  Using Positive Deviance in the prevention and control of MRSA infections in a Colombian hospital: a time-series analysis.

Authors:  N M Olarte Escobar; I A Valderrama Márquez; J Avila Quiroga; T Goretty Trujillo; F González; M I Garzón Aguilar; J Escobar-Pérez
Journal:  Epidemiol Infect       Date:  2017-01-09       Impact factor: 4.434

2.  Availability of secondary healthcare data for conducting pharmacoepidemiology studies in Colombia: A systematic review.

Authors:  Juan-Sebastian Franco; David Vizcaya
Journal:  Pharmacol Res Perspect       Date:  2020-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.